Loading stock data…
$2.04-0.06 (-2.86%)
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia.
Jyong Biotech Ltd. in the Healthcare sector is trading at $2.04 with a market capitalization of $159M. The stock is currently near its 52-week low of $1.43, remaining 10.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|
| Total Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Income | — | — | — | — |
| Net Income | — | — | — | — |
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign...